哈萨克斯坦、波兰和保加利亚利益相关者在卫生技术评估中的参与情况。
Stakeholders' Involvement in Health Technology Assessment in Kazakhstan, Poland and Bulgaria.
作者信息
Kulembekova Lyazzat, Hailey David, Kulzhanov Maksut, Tabarov Adlet, Georgiev Svetlin, Jaworzynska Magdalena, Yanakieva Antoniya Yordanova, Kosherbayeva Lyazzat
机构信息
Health Policy and Management Department, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
School of Information Sciences and Computer Technology, University of Wollongong, Wollongong, Australia.
出版信息
Patient Prefer Adherence. 2024 May 22;18:1009-1015. doi: 10.2147/PPA.S455838. eCollection 2024.
BACKGROUND
In recent years, involvement of healthcare stakeholders in health technology assessment (HTA) has been discussed as helping the inclusion of social values in the decision-making process. The aim of our research was to identify and compare details from Kazakhstan, Poland and Bulgaria on their stakeholders' involvement in the HTA process. Information was sought on their identification, responsibilities, and regulation.
METHODS
We conducted a survey of seven types of stakeholders in the healthcare systems of Kazakhstan, Poland, and Bulgaria. They included patients and the public, providers, purchasers, payers, policy makers, product makers, and principal investigators. They were questioned on their involvement in the HTA process, and on the objectives of their participation.
RESULTS
Levels of involvement of different kinds of stakeholder varied between countries, reflecting political and administrative developments. There was full or partial agreement on the objectives of stakeholder participation. All respondents agreed that representatives of the ministry of health should be involved in selection of stakeholders for HTA.
CONCLUSION
Progress has been made in the involvement of stakeholders, with interest in further development in all three countries.
背景
近年来，医疗保健利益相关者参与卫生技术评估（HTA）被认为有助于将社会价值观纳入决策过程。我们研究的目的是识别和比较哈萨克斯坦、波兰和保加利亚在其利益相关者参与HTA过程方面的详细情况。收集了有关其识别、职责和监管方面的信息。
方法
我们对哈萨克斯坦、波兰和保加利亚医疗保健系统中的七种利益相关者进行了调查。他们包括患者及公众、提供者、购买者、支付者、政策制定者、产品制造商和主要研究者。询问了他们参与HTA过程的情况以及参与的目标。
结果
不同类型利益相关者的参与程度在各国之间有所不同，反映了政治和行政方面的发展情况。在利益相关者参与的目标上存在完全或部分共识。所有受访者都同意卫生部的代表应参与HTA利益相关者的选择。
结论
在利益相关者参与方面已取得进展，所有三个国家都有意进一步发展。
Zotero 插件